Rwanda, is gearing up for the inauguration of a new state-of-the-art mRNA vaccine manufacturing plant, a project of German biotechnology company BioNTech, scheduled for December 18. This development marks a significant stride in Africa’s journey towards self-sufficient healthcare solutions.
According to Africa News Agency, the establishment of the BioNTech facility in Rwanda’s Special Economic Zone in the Gasabo District was initiated by a memorandum of understanding signed in 2021. The plant, which began construction in June 2022, spans approximately 30,000 square meters and includes BioNTainers for the production of mRNA and formulated bulk drug products. The facility represents a major advancement in Rwanda’s biotechnological capabilities and its contribution to global health.